Graham, C., Puliafito, B., Raje, N., Cirstea, D., Branagan, A., Yee, A., Horick, N., Cook, D., Lindell, K., Bernier, D., Barselau, A., Furman, G., Ekstrom, M., Emmett, J., King, M., Chowdhury, M. R., Supper, V., Donner, H., Leick, M., Blumenberg, V., Parker, A., Harris, D. L., Lee, W., Graham, K., Wiggin, H., Schneider, P., Ritz, J., Nikiforow, S., Daley, H., Armant, M., Huang, L., Gallagher, K. M., Frigault, M., Maus, M. (2025). First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance. Blood. https://doi.org/10.1182/blood-2025-270